Xeris Biopharma Holdings
XERS
230 hedge funds and large institutions have $789M invested in Xeris Biopharma Holdings in 2025 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 77 increasing their positions, 61 reducing their positions, and 28 closing their positions.
396% more call options, than puts
Call options by funds: $3.88M | Put options by funds: $782K
111% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 28
87% more capital invested
Capital invested by funds: $422M → $789M (+$366M)
26% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 61
15% more funds holding
Funds holding: 200 → 230 (+30)
2.14% more ownership
Funds ownership: 57.85% → 59.99% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$13.3M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.3M |
| 3 |
Jane Street
New York
|
+$5.86M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$5.84M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16M |
| 2 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$5.95M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$4.11M |
| 4 |
Goldman Sachs
New York
|
-$3.16M |
| 5 |
Legal & General Group
London,
United Kingdom
|
-$2.97M |
XERS Hedge Fund Activity: Q3 2025 in Review
230 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2025, worth a combined $789M — up 87% from $422M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new XERS positions and 28 closed out — a net gain of 31 holders — while 77 added to existing stakes and 61 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $13.3M. The largest seller was Millennium Management, cutting an estimated $16M.
- 230 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2025, up from 200 in Q2 2025.
- Funds reported $789M of Xeris Biopharma Holdings stock for Q3 2025, up 87% quarter-over-quarter.
- 59 funds opened new Xeris Biopharma Holdings positions in Q3 2025 and 28 closed out, a net change of +31 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2025 was D.E. Shaw & Co, an estimated $13.3M added.
- The largest Xeris Biopharma Holdings seller in Q3 2025 was Millennium Management, an estimated $16M sold.
Based on aggregated 13F filings for Q3 2025.